• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Serevent (salmeterol xinafoate) Jan 2003

Audience: Pulmonary specialists and other healthcare professionals

GlaxoSmithKline notified healthcare professionals of important new safety information on use of Serevent in patients with asthma. Recent findings from an interim analysis of a large Serevent safety study have prompted further review of the potential association between Serevent and rare, but potentially serious, respiratory adverse events.

[January 23, 2003 - Letter - FDA]